Different Name, Same Great Oncology Resource

Share this content:
Different Name, Same Great Oncology Resource
Different Name, Same Great Oncology Resource

Dear CTA Readers,

The field of oncology is an ever-changing, dynamic discipline, and cancer research and subsequent new treatments are evolving at a rapid pace. Treating a patient with cancer is not just about chemotherapy anymore; it can include any number of therapies, including radiation, surgery, and immunotherapy, to name just a few. As a website whose mission is to provide oncology professionals with a wide range of practical knowledge, including comprehensive clinical and drug information that reflects current and emerging principles of cancer care to optimize patient outcomes, we need to evolve and react as well.

Therefore, I'm proud to announce that we are changing the name of our website to Cancer Therapy Advisor, to better reflect the current state of oncology today. Our goal, first and foremost, is to inform oncology decisions, and our new tagline states just that. We want you, the oncology professional, to look to CancerTherapyAdvisor.com as a comprehensive resource that offers a wide range of informative and educational content on all oncology topics, including treatment-focused information about targeted therapies, biologics, immunotherapy, vaccines, radiotherapy, chemotherapy, and supportive care options, which will ultimately help you to better care for your patients.

The look and feel of the website will not change, and all of the content you're used to seeing on ChemotherapyAdvisor.com will still be here on CancerTherapyAdvisor.com, such as cancer treatment regimens, expert viewpoints, latest news, and more. Our continuing goal is to develop unique, informational articles and news stories that are of interest to you and relevant to your current practice. And, don't forget we are always open to feedback and topic ideas, particularly if you feel there is an area of oncology that needs more attention and should be explored further. Email editor@chemotherapyadvisor.com with any thoughts you'd like to share, particularly about our new name and tagline.

Lastly, I want to thank you for your loyal readership and for helping to make us the high-quality, respected oncology website we are today. And if this is your first time at Cancer Therapy Advisor, welcome! I hope you enjoy what we have to offer and that you will visit us again.

Nora Ray
Associate Editorial Director, Cancer Therapy Advisor

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs